What is the appropriate dose of upadacitinib (Rinvoq) for a child weighing 12.5 kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Upadacitinib Dosing for a Child Weighing 12.5 kg

For a child weighing 12.5 kg, upadacitinib is dosed as 3 mg (3 mL of RINVOQ LQ oral solution) twice daily.

Weight-Based Dosing Algorithm

According to the FDA-approved prescribing information for RINVOQ LQ, pediatric dosing is strictly weight-based for approved indications (psoriatic arthritis and polyarticular juvenile idiopathic arthritis in children ≥2 years) 1:

  • 10 kg to less than 20 kg: 3 mg (3 mL oral solution) twice daily
  • 20 kg to less than 30 kg: 4 mg (4 mL oral solution) twice daily
  • 30 kg and greater: 6 mg (6 mL oral solution) twice daily OR 15 mg tablet once daily

At 12.5 kg, this child falls into the 10-20 kg weight category, requiring 3 mg twice daily using the oral solution.

Critical Administration Details

Formulation Requirements

  • RINVOQ LQ oral solution is NOT substitutable with RINVOQ extended-release tablets 1
  • The oral solution must be administered using the provided press-in bottle adapter and oral dosing syringe
  • Dosing is twice daily for the oral solution (not once daily like tablets)
  • Can be given with or without food

Age and Indication Restrictions

The FDA has only approved upadacitinib in pediatric patients for:

  • Psoriatic arthritis: Age ≥2 years, weight ≥10 kg 1
  • Polyarticular juvenile idiopathic arthritis: Age ≥2 years, weight ≥10 kg 1

Upadacitinib is NOT approved for atopic dermatitis in children under 12 years of age 1. For atopic dermatitis, approval begins at age 12 years with weight ≥40 kg at a dose of 15 mg once daily 2, 1.

Pre-Treatment Evaluation Requirements

Before initiating upadacitinib at any dose, the following evaluations are mandatory 1:

  1. Tuberculosis screening (active and latent)
  2. Viral hepatitis screening (hepatitis B and C)
  3. Complete blood count: Do not initiate if:
    • Absolute lymphocyte count <500 cells/mm³
    • Absolute neutrophil count <1000 cells/mm³
    • Hemoglobin <8 g/dL
  4. Hepatic function: Do not use in severe hepatic impairment (Child-Pugh C)
  5. Update immunizations according to current guidelines before starting therapy

Monitoring During Treatment

Based on JAK inhibitor consensus guidelines 3, 4:

  • Month 1 and 3: CBC with differential, liver enzymes, renal function
  • Every 3 months thereafter: CBC with differential, liver enzymes, renal function
  • At 3 months: Lipid panel (then annually)
  • Ongoing: Monitor for infections, particularly herpes zoster

Laboratory-Based Dose Adjustments

Interrupt treatment if 3:

  • Absolute neutrophil count 500-1000/mm³ (on two sequential measures)
  • Absolute lymphocyte count 500-750/mm³ (on two sequential measures)
  • Hemoglobin decreases by ≥2 g/dL or falls below 8 g/dL

Common Pitfalls to Avoid

  1. Do not use tablet formulation in children <30 kg: The extended-release tablets are only appropriate for children ≥30 kg; lighter children require the oral solution 1

  2. Do not dose once daily with oral solution: Unlike tablets, the oral solution is dosed twice daily—missing this distinction leads to underdosing

  3. Do not use off-label for atopic dermatitis in young children: While emerging research suggests potential benefit 5, 6, 7, there is no FDA approval or established safety data for children <12 years with atopic dermatitis

  4. Do not combine with other immunosuppressants: Avoid concurrent use with other JAK inhibitors, biologics, or potent immunosuppressants like azathioprine or cyclosporine 1

  5. Do not give live vaccines during treatment: Update all immunizations, including recombinant zoster vaccine if age-appropriate, before starting therapy 3, 4

Safety Considerations in Pediatric Patients

The FDA black box warnings for upadacitinib include increased risks of serious infections, malignancy, major adverse cardiovascular events, and thrombosis 1. While these warnings are based primarily on adult data (particularly the ORAL Surveillance trial in rheumatoid arthritis patients ≥50 years with cardiovascular risk factors 4), careful patient selection and monitoring remain essential in pediatric populations.

Emerging pediatric case series suggest reasonable tolerability at 15 mg daily in adolescents 6, 7, but long-term safety data in younger children remain limited. The 3 mg twice daily dosing for a 12.5 kg child represents weight-adjusted exposure comparable to approved adult dosing.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.